Scarica l'app Stockscreener
5.61
12.20%
0.61
Dopo l'orario di chiusura:
5.54
-0.07
-1.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAGE Giù?
Forum
Previsione
Precedente Chiudi:
$5.00
Aprire:
$5.06
Volume 24 ore:
4.31M
Relative Volume:
4.97
Capitalizzazione di mercato:
$343.18M
Reddito:
$91.06M
Utile/perdita netta:
$-503.14M
Rapporto P/E:
-0.5655
EPS:
-9.92
Flusso di cassa netto:
$-424.74M
1 W Prestazione:
+4.18%
1M Prestazione:
+14.26%
6M Prestazione:
-47.42%
1 anno Prestazione:
-73.13%
Intervallo 1D:
$4.95
$5.62
Intervallo di 1 settimana:
$4.94
$5.62
Portata 52W:
$4.62
$28.26
Sage Therapeutics Inc Stock (SAGE) Company Profile
Nome
Sage Therapeutics Inc
Settore
Industria
Telefono
617-299-8380
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Confronta SAGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
5.61 | 343.18M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-21 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-29 | Iniziato | Citigroup | Sell |
| 2024-05-29 | Iniziato | Robert W. Baird | Neutral |
| 2024-04-17 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-08-08 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Downgrade | Goldman | Buy → Neutral |
| 2023-08-08 | Downgrade | Needham | Buy → Hold |
| 2023-08-07 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-08-07 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Downgrade | Stifel | Buy → Hold |
| 2023-08-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-03-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-03-31 | Iniziato | Berenberg | Hold |
| 2021-11-02 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-16 | Downgrade | Citigroup | Buy → Neutral |
| 2021-04-07 | Iniziato | Piper Sandler | Overweight |
| 2021-02-26 | Downgrade | Mizuho | Buy → Neutral |
| 2021-02-25 | Reiterato | H.C. Wainwright | Neutral |
| 2021-02-02 | Ripresa | Raymond James | Mkt Perform |
| 2021-01-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-01-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Reiterato | H.C. Wainwright | Neutral |
| 2020-09-11 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-08-10 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-04-08 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-28 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-06 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-12-05 | Reiterato | Guggenheim | Buy |
| 2019-12-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-10-30 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-23 | Iniziato | Wedbush | Outperform |
| 2019-04-25 | Iniziato | Jefferies | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Sage Therapeutics Inc Borsa (SAGE) Ultime notizie
Postpartum Depression Therapeutics Market Size in the 7MM was ~USD 260 Million in 2023, is expected to grow by 2034, and estimates DelveInsight - The Globe and Mail
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Sage Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsSAGE - The Eastern Progress Online
Brokerages Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $11.53 - MarketBeat
Sage Therapeutics price target lowered to $6 from $10 at Stifel - Yahoo Finance
Where Sage Therapeutics Stands With Analysts - Benzinga
Stifel Nicolaus Has Lowered Expectations for Sage Therapeutics (NASDAQ:SAGE) Stock Price - MarketBeat
Sage Therapeutics' SWOT analysis: navigating challenges in CNS drug stock - Investing.com
Sage Therapeutics' SWOT analysis: navigating challenges in CNS drug stock By Investing.com - Investing.com UK
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
Levi & Korsinsky Notifies Sage Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSAGE - The Eastern Progress Online
Layoff Tracker: Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff - BioSpace
Sage Therapeutics shares stay Neutral rated by Mizuho, target cut on discontinued pipeline - Investing.com UK
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Fmr LLC - MarketBeat
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class ActionSAGE - The Eastern Progress Online
Investors who lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class ActionSAGE - The Eastern Progress Online
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seeking Recovery for InvestorsContact The Gross Law Firm - The Eastern Progress Online
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc.(SAGE) Shareholders - The Eastern Progress Online
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
RTW Investments LP Buys 111,123 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
RBC Capital Upgrades Sage Therapeutics (SAGE) - MSN
Deutsche Bank Initiates Coverage of Sage Therapeutics (SAGE) with Hold Recommendation - MSN
Sage Therapeutics, Inc. Announces Retirement of Jeffrey M. Jonas as Member of Board of Directors , Effective December 1, 2024 - Marketscreener.com
Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Member of Board of Directors , Effective December 1, 2024 - Marketscreener.com
SAGE (Sage Therapeutics) Change In Inventory : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
SAGE (Sage Therapeutics) Cash Flow from Financing : $10.4 Mil (TTM As of Sep. 2024) - GuruFocus.com
Rx Rundown: Novartis, Sage Therapeutics, Eli Lilly and more - MM+M Online
Sage Therapeutics announces board member retirement By Investing.com - Investing.com Nigeria
Sage Therapeutics announces board member retirement - Investing.com India
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks By Investing.com - Investing.com South Africa
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - BioSpace
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks - Investing.com
Sage Therapeutics Inc Azioni (SAGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sage Therapeutics Inc Azioni (SAGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| IGUCHI KIMI | CFO & Treasurer |
Jan 02 '24 |
Option Exercise |
1.36 |
1,642 |
2,233 |
70,429 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):